194 related articles for article (PubMed ID: 22273482)
1. Meta-analysis: antiviral treatment for hepatitis D.
Triantos C; Kalafateli M; Nikolopoulou V; Burroughs A
Aliment Pharmacol Ther; 2012 Mar; 35(6):663-73. PubMed ID: 22273482
[TBL] [Abstract][Full Text] [Related]
2. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
[TBL] [Abstract][Full Text] [Related]
3. Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials.
Lamers MH; Kirgiz ÖÖ; Heidrich B; Wedemeyer H; Drenth JP
Antivir Ther; 2012; 17(6):1029-37. PubMed ID: 22892440
[TBL] [Abstract][Full Text] [Related]
4. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials.
Shi Y; Wu YH; Shu ZY; Zhang WJ; Yang J; Chen Z
Hepatobiliary Pancreat Dis Int; 2010 Oct; 9(5):462-72. PubMed ID: 20943454
[TBL] [Abstract][Full Text] [Related]
5. Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: a multicenter Romanian trial.
Gheorghe L; Iacob S; Simionov I; Vadan R; Constantinescu I; Caruntu F; Sporea I; Grigorescu M
J Gastrointestin Liver Dis; 2011 Dec; 20(4):377-82. PubMed ID: 22187703
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
[TBL] [Abstract][Full Text] [Related]
8. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
9. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
12. Chronic hepatitis C treatment in näive patients.
Daruich J
Ann Hepatol; 2010; 9 Suppl():65-71. PubMed ID: 20713999
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis.
Abdrakhman A; Ashimkhanova A; Almawi WY
Antiviral Res; 2021 Jan; 185():104995. PubMed ID: 33321155
[TBL] [Abstract][Full Text] [Related]
14. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience.
Abbas Z; Memon MS; Mithani H; Jafri W; Hamid S
Antivir Ther; 2014; 19(5):463-8. PubMed ID: 24423484
[TBL] [Abstract][Full Text] [Related]
16. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
[TBL] [Abstract][Full Text] [Related]
17. Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Anastasiou OE; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Heidrich B; Mederacke I; von der Leyen H; Kahlhöfer J; von Karpowitz M; Hardtke S; Cornberg M; Yurdaydin C; Wedemeyer H
Liver Int; 2024 Jan; 44(1):139-147. PubMed ID: 37787009
[TBL] [Abstract][Full Text] [Related]
18. Current management of delta hepatitis.
Rizzetto M
Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
